



Without action, it is estimated that **39.1 million**¹ people will die of multidrug resistant infection worldwide between 2025–2050




Centauri Therapeutics is an immunotherapy company

They have developed proprietary Alphamer[®] technology – a novel first-in-class approach to tackling infection



The Alphamer[®] technology can redirect naturally existing antibodies to kill bacteria



A promising lead compound has been identified with both direct antibacterial activity and the ability to recruit the immune system




PACE 

Funding and support from PACE will allow the team to

- Modify the molecular structure to maximise immune recruitment
- Further optimise antimicrobial properties
- Ensure the drug is safe and effective

If successful, this therapy would be used to treat people with hospital and ventilator acquired pneumonia

It would help vulnerable patients, including those with cancer



1. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
Naghavi, Mohsen *et al.* The Lancet, Volume 404, Issue 10459, 1199 - 1226